Therapy with ruxolitinib, a potent JAK1/JAK2 inhibitor approved for the treatment of MF-related splenomegaly or symptoms, can be associated with dose-dependent anemia, mostly emerging in the first 12 weeks of treatment. Here, JAK2 is linked to anemia.